摘要
随着内分泌治疗药物的发展，新辅助内分泌治疗成为近年来乳腺癌研究的又一热点。大量试验证明，新辅助内分泌治疗能降低肿瘤分期，提高乳腺癌的局部控制率，进一步提高保乳手术率，其中第3代芳香化酶抑制剂的疗效可能优于三苯氧胺。
With the development of endocrine drugs, neoadjuvant endocrine therapy becomes the hotspot of the research on breast cancer. A lot of studies have proved that neoadjuvant endocrine therapy can degrade the tumor staging,increase the local control rate and breast-conserving rates. And the therapeutic effect of the third generation aromatase inhibitor is superior to that of tamoxifen.
出处
《国际肿瘤学杂志》
CAS
2010年第1期56-60,共5页
Journal of International Oncology
关键词
乳腺肿瘤
内分泌治疗
Breast neoplasms
Endocrine therapy
